Katherine Rielly-Gauvin Sells 18,393 Shares of Liquidia (NASDAQ:LQDA) Stock

Liquidia Corporation (NASDAQ:LQDA) Director Katherine Rielly-Gauvin sold 18,393 shares of the company’s stock in a transaction on Thursday, August 20th. The shares were sold at an average price of $72.23, for a total value of $1,328,526.39. Following the sale, the director directly owned 44,637 shares of the company’s stock, valued at approximately $3,224,130.51. This represents a 29.18% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Katherine Rielly-Gauvin also recently made the following trade(s):

• On Wednesday, August 19th, Katherine Rielly-Gauvin sold 36,789 shares of Liquidia stock. The shares were sold at an average price of $74.99, for a total value of $2,758,807.11.

Liquidia Stock Down 3.4%

Shares of Liquidia stock opened at $68.62 on Friday. The stock has a 50-day moving average price of $79.29 and a 200 day moving average price of $56.21. The company has a market cap of $6.14 billion, a P/E ratio of 50.09 and a beta of 0.58. The company has a current ratio of 2.31, a quick ratio of 2.12 and a debt-to-equity ratio of 0.63. Liquidia Corporation has a 1 year low of $21.15 and a 1 year high of $93.61.

Liquidia (NASDAQ:LQDA) last released its earnings results on Wednesday, August 12th. The company reported $0.74 earnings per share for the quarter, missing the consensus estimate of $0.76 by ($0.02). The business had revenue of $171.68 million for the quarter, compared to analysts’ expectations of $168.48 million. Liquidia had a net margin of 30.74% and a return on equity of 149.65%. The company’s revenue was up 1842.1% compared to the same quarter last year. During the same period last year, the firm earned ($0.49) EPS. As a group, analysts expect that Liquidia Corporation will post 2.57 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of research analysts recently commented on the stock. Bank of America boosted their price objective on shares of Liquidia from $79.00 to $92.00 and gave the company a “neutral” rating in a research report on Thursday, August 13th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Liquidia in a research report on Friday, July 17th. Oppenheimer set a $75.00 target price on shares of Liquidia in a research note on Friday, June 5th. Wells Fargo & Company boosted their price target on shares of Liquidia from $62.00 to $108.00 and gave the company an “overweight” rating in a report on Thursday, August 13th. Finally, Raymond James Financial reaffirmed a “strong-buy” rating and issued a $106.00 price target on shares of Liquidia in a research note on Thursday, August 13th. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, three have issued a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $98.08.

Institutional Investors Weigh In On Liquidia

Institutional investors have recently made changes to their positions in the company. Northwestern Mutual Wealth Management Co. bought a new stake in shares of Liquidia in the 4th quarter valued at approximately $25,000. Covestor Ltd raised its position in Liquidia by 41.9% during the fourth quarter. Covestor Ltd now owns 1,216 shares of the company’s stock valued at $42,000 after acquiring an additional 359 shares in the last quarter. NewEdge Advisors LLC bought a new position in Liquidia during the second quarter valued at approximately $25,000. Globeflex Capital L P acquired a new stake in Liquidia in the second quarter valued at approximately $175,000. Finally, Nykredit A S acquired a new stake in Liquidia in the second quarter valued at approximately $177,000. 64.54% of the stock is currently owned by institutional investors and hedge funds.

About Liquidia

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).